A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread

NCT02322814 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

169

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor's decision

Conditions

Breast Cancer

Interventions

DRUG: Cobimetinib
DRUG: Paclitaxel
DRUG: Placebo
DRUG: Atezolizumab
DRUG: Nab-Paclitaxel

Sponsor

Hoffmann-La Roche